In omega-3 fatty acid studies, EPA alone leads to a greater reduction in cardiovascular risk compared to EPA plus DHA

0
69

Source / information

Published by:

Disclosure:
Khan does not report any relevant financial information. Please refer to the study for all relevant financial information from the other authors.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

In a meta-analysis of omega-3 fatty acid studies, eicosapentaenoic acid monotherapy resulted in the greatest reduction in cardiovascular risk compared to a combination of eicosapentaenoic acid and docosahexaenoic acid.

Deepak L. Bhatt

“In this systematic review and meta-analysis, we found moderate evidence security that omega-3s are beneficial for reducing cardiovascular mortality and outcomes,” said Cardiology Today Intervention Section Editor Deepak L. Bhatt, MD, MPH, Executive Director, Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, and colleagues wrote in eClinical Medicine. “The magnitude of the relative reductions was robust in eicosapentaenoic acid (EPA) studies compared to that of eicosapentaenoic acid / docosahexaenoic acid (DHA), suggesting different effects of EPA and DHA in reducing cardiovascular risk.”

Omega 3

Source: Adobe Stock

Bhatt and colleagues analyzed the effectiveness of omega-3 fatty acids on the CV results and examined the variability of EPA compared to a combination of EPA and DHA. Researchers assessed cardiovascular mortality, non-fatal cardiovascular outcomes, bleeding, and atrial fibrillation in a meta-analysis of 38 randomized clinical trials of omega-3 fatty acids, categorized for EPA monotherapy or EPA / DHA therapy.

The analyzed clinical studies were published before June 7, 2021. In 149,051 people who participated in the 38 studies, omega-3 fatty acid intake correlated with a reduced risk of cardiovascular mortality (RR = 0.93; 95% CI 0.88-0.98), non-fatal MI (RR = 0.87; 95% CI, 0.81-0.93), CHD events (RR = 0.91; 95% CI, 0.87-0.96), serious adverse cardiovascular Events (RR = 0.95; 95% CI, 0.92-0.98) and revascularization (RR = 0.91; 95% CI, 0.87-0.95).

Bhatt and colleagues observed greater risk reductions with EPA monotherapy than with EPA / DHA for cardiovascular mortality, non-fatal MI, CHD events, major adverse cardiovascular events, and revascularization.

However, according to the researchers, monotherapy was at a higher risk for whole bleeding (RR = 1.49; 95% CI 1.2-1.84) and AF (RR = 1.35; 95% CI 1.1-1.66 ) connected. However, EPA monotherapy also correlated with a reduction in non-fatal strokes.

“This meta-analysis sheds light on the role of omega-3 fatty acids, especially prescription EPA,” said Bhatt in a press release. “It should encourage researchers to further study the cardiovascular effects of EPA in different clinical settings.”

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

LEAVE A REPLY

Please enter your comment!
Please enter your name here